Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation
Benralizumab provided substantial improvements in eosinophilic inflammation, exacerbation frequency, symptom control, and lung function over 32 weeks in a real-life SEA cohort. These findings support benralizumab as an effective and well-tolerated therapeutic option in routine clinical practice. .
Authors
- Şeyma Özden (ORCID: https://orcid.org/0000-0002-6646-9894)
- Mustafa Asım Demirkol (ORCID: https://orcid.org/0000-0001-6490-447X)
- Hasan Furkan Avcı (ORCID: https://orcid.org/0000-0002-5972-1828)
- Mazlum Dursun
- Nihal Yildirim
- Yunus Bozkurt
- Aysun Aynacı
- Fatma Merve Tepetam
- Fatma Terzioğlu Şahin
Institutions
- University of Health Science (KH)
- Sağlık Bilimleri Üniversitesi (TR)
- University of Health Sciences Antigua (AG)
Publication Details
- Journal
- International Archives of Allergy and Immunology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1159/000550316
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00